Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017

John Greenwood; Margareta Hammarlund-Udenaes; Hazel C Jones; Alan W Stitt; Roosmarijn E Vandenbroucke; Ignacio A Romero; Matthew Campbell; Gert Fricker; Birger Brodin; Heiko Manninga; Pieter J Gaillard; Markus Schwaninger; Carl Webster; Krzysztof B Wicher; Michel Khrestchatisky

doi:10.1186/s12987-017-0079-9

Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017

Fluids Barriers CNS. 2017 Nov 7;14(1):31. doi: 10.1186/s12987-017-0079-9.

Authors

John Greenwood¹, Margareta Hammarlund-Udenaes², Hazel C Jones³, Alan W Stitt⁴, Roosmarijn E Vandenbroucke^{5

6}, Ignacio A Romero⁷, Matthew Campbell⁸, Gert Fricker⁹, Birger Brodin¹⁰, Heiko Manninga¹¹, Pieter J Gaillard¹², Markus Schwaninger¹³, Carl Webster¹⁴, Krzysztof B Wicher¹⁵, Michel Khrestchatisky^{16

17}

Affiliations

¹ Institute of Ophthalmology, University College London, London, EC1V 9EL, UK.
² Department of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden.
³ Gagle Brook House, Chesterton, Bicester, OX26 1UF, UK. [email protected].
⁴ Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
⁵ Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
⁶ VIB-UGent Center for Inflammation Research, VIB, Ghent, Belgium.
⁷ School of Life, Health and Chemical Sciences, Open University, Milton Keynes, UK.
⁸ Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.
⁹ Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls University, Heidelberg, Germany.
¹⁰ Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
¹¹ NEUWAY Pharma GmbH, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.
¹² 2-BBB Medicines BV, Leiden, Netherlands.
¹³ Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.
¹⁴ Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
¹⁵ Ossianix Inc., Stevenage, UK.
¹⁶ CNRS, NICN, Aix Marseille Univ, Marseille, France.
¹⁷ Vect-Horus, Faculte de Medecine Nord, 51 Boulevard Pierre Dramard, Marseille, France.

Abstract

This is a report on the CNS barrier congress held in London, UK, March 22-23rd 2017 and sponsored by Kisaco Research Ltd. The two 1-day sessions were chaired by John Greenwood and Margareta Hammarlund-Udenaes, respectively, and each session ended with a discussion led by the chair. Speakers consisted of invited academic researchers studying the brain barriers in relation to neurological diseases and industry researchers studying new methods to deliver therapeutics to treat neurological diseases. We include here brief reports from the speakers.

Keywords: Antibody therapy; Blood–CSF barrier; Blood–brain barrier; Blood–retinal barrier; Drug delivery; Liposomal technology; MicroRNA; Neuroinflammation; Protein capsules; Viral vectors.

Publication types

Congress

MeSH terms

Animals
Blood-Brain Barrier*
Central Nervous System
Humans
Nervous System Diseases / drug therapy*